2. Peptides
  3. Peptide and Derivatives
  4. Peptides for Drug Delivery

Peptides for Drug Delivery

Custom Peptide Synthesis
 

Peptides for Drug Delivery (301):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P0023
    Cyclo(-RGDfK) 161552-03-0 99.48%
    Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface.
    Cyclo(-RGDfK)
  • HY-P0036
    Octreotide 83150-76-9 99.64%
    Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly.
    Octreotide
  • HY-P4108
    TAT-HA2 Fusion Peptide 923954-79-4 99.93%
    TAT-HA2 Fusion Peptide is a peptide-based delivery agent that combines the pH-sensitive HA2 fusion peptide from Influenza and the cell-penetrating peptide TAT from HIV. TAT-HA2 Fusion Peptide is a transactivator of transcription and hemaglutanin for endosomal release. TAT-HA2 Fusion Peptide enhances cellular uptake of macromolecules.
    TAT-HA2 Fusion Peptide
  • HY-P0084
    Cyclic somatostatin 38916-34-6 99.77%
    Cyclic somatostatin (SRIF-14) is a growth hormone-release inhibiting factor used in the research of severe, acute hemorrhages of gastroduodenal ulcers. Cyclic somatostatin is a neuropeptide co-stored with acetylcholine in the cardiac parasympathetic innervation, exerts influences directly on contraction of ventricular cardiomyocytes. Cyclic somatostatin inhibits the contractile response of isoprenaline with an IC50 value of 13 nM. Cyclic somatostatin can be used for the research of cardiovascular disease.
    Cyclic somatostatin
  • HY-106244A
    DOTATATE acetate 177943-89-4 99.82%
    DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT).
    DOTATATE acetate
  • HY-P10557
    DAG peptide 99.61%
    DAG peptide is a cyclic peptide. DAG peptide selectively recognizes a subset of astrocytes that are activated in Alzheimer's disease (AD) starting at an early stage of the disease. DAG peptide can be used as a tool to enhance the delivery of therapeutics and imaging agents to sites of vascular changes and astrogliosis in diseases associated with neuroinflammation.
    DAG peptide
  • HY-164166
    Fmoc-Sar-Sar-Sar-OH 2749824-37-9
    Fmoc-Sar-Sar-Sar-OH is a small molecule polypeptide composed of four sarcosine residues, in which the N-terminus of the peptide chain is protected by Fmoc. Fmoc-Sar-Sar-Sar-OH can be used for peptide synthesis or synthesis of drug-peptide ligand conjugates.
    Fmoc-Sar-Sar-Sar-OH
  • HY-D2363
    DOTA.SA.FAPi TFA 99.26%
    DOTA.SA.FAPi TFA is a bifunctional DATA5m and DOTA chelator, which is composed of the squaric acid and UAMC1110. DOTA.SA.FAPi TFA inhibits fibroblast activation protein (FAP) with an IC50 of 0.9 nM. DOTA.SA.FAPi TFA targets protease PREP with an IC50 of 5.4 μM. DOTA.SA.FAPi TFA can be used a PET tracer, when labeled with 68Ga, and used for research about cancer.
    DOTA.SA.FAPi TFA
  • HY-P0122
    iRGD peptide 1392278-76-0 98.79%
    iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.
    iRGD peptide
  • HY-P2300
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) 862772-11-0 99.70%
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors.
    Cyclo(Arg-Gly-Asp-D-Phe-Cys)
  • HY-106244
    DOTATATE 177943-88-3 99.87%
    DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT).
    DOTATATE
  • HY-P2341
    Angiopep-2 hydrochloride 99.74%
    Angiopep-2 hydrochloride is a brain peptide vector. The conjugation of anticancer agents with the Angiopep-2 peptide vector could increase their efficacy in the treatment of brain cancer.
    Angiopep-2 hydrochloride
  • HY-100563
    Cyclo(RGDyK) trifluoroacetate 250612-42-1 99.92%
    Cyclo(RGDyK) trifluoroacetate is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.
    Cyclo(RGDyK) trifluoroacetate
  • HY-P4094
    CTP 1052692-86-0 98.45%
    CTP is a cardiac targeting peptide. CTP transduces cardiomyocytes in vitro. CTP leads to efficient and specific transduction of heart tissue in mice model. CTP can be used to deliver therapeutic peptides, proteins and nucleic acid specifically to the heart.
    CTP
  • HY-P1848
    Pep-1 (uncapped) 395069-86-0 99.27%
    Pep-1 (uncapped) is a cell-penetrating peptide.
    Pep-1 (uncapped)
  • HY-100563A
    Cyclo(RGDyK) 217099-14-4 99.76%
    Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.
    Cyclo(RGDyK)
  • HY-106033
    Edotreotide 204318-14-9 98.15%
    Edotreotide is a somatostatin analogue. Edotreotide bound to various radionuclides, has the potential for the research and diagnosis of certain types of cancer.
    Edotreotide
  • HY-153549
    Pentixafor 1341207-62-2 99.20%
    Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with 68Gallium (68Ga) for positron emission tomography (PET) imaging.
    Pentixafor
  • HY-P0023A
    Cyclo(-RGDfK) TFA 500577-51-5 99.82%
    Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface.
    Cyclo(-RGDfK) TFA
  • HY-P5307
    Peptide A5K 99.08%
    Peptide A5K (INF7-A5K-TAT) is an RNP delivery peptide that delivers CRISPR RNPs to T cells. Peptide A5K effectively edits T cells without substantial impact on T cell viability.
    Peptide A5K